About: El suplemento con altas dosis de vitamina D podría representar una alternativa promisoria para prevenir o tratar la infección por COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: El suplemento con altas dosis de vitamina D podría representar una alternativa promisoria para prevenir o tratar la infección por COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	El suplemento con altas dosis de vitamina D podría representar una alternativa promisoria para prevenir o tratar la infección por COVID-19
Creator	Ferder, León Inserra, Felipe Manucha, Walter Mariani, Javier Tajer, Carlos Mansur, José
Source	Elsevier; Medline; PMC
abstract	Resumen Si bien carecemos de suficiente evidencia que justifique suplementar con vitamina D en la prevención y/o tratamiento de la infección por COVID-19, a la fecha resulta cada vez más factible que esta hipótesis sea válida. Dos mecanismos básicos generales deberían ser considerados. Uno sería la acción anti-infecciosa e inmuno-moduladora que ejerce mejorando las barreras intercelulares por estímulo de la inmunidad innata, así también por modulación de la inmunidad adaptativa. También, la vitamina D reduce la producción de citoquinas inflamatorias como IL-2 e interferón gamma (INFγ). Más recientemente se han demostrado múltiples efectos pleiotrópicos sobre las acciones de vitamina D a nivel anti-inflamatorio e inmuno-modulador. Esto explica resultados positivos en estudios con influenza, coronavirus y otras infecciones respiratorias. Se ha descripto relación inversa entre niveles séricos de vitamina D y prevalencia de patología infecciosa respiratoria. De interés, otro abordaje mecanístico responde a considerar la inhibición del sistema renina-angiotensina-aldosterona, que se exacerba en la infección por COVID-19 debido a que el virus se une a la enzima ECA2, quedando disponible más angiotensina II para causar daño. La vitamina D inhibe mediadores del SRAA -presente en todas las células del organismo-, y por inhibir la actividad ECA y aumentar la ECA2, disminuye los niveles de angiotensina II. Presentamos estudios con propuestas de dosis recomendadas de vitamina D y aunque no quede concretada una única guía, los posibles beneficios son promisorios. Finalmente, el propósito de la presente revisión es compartir esta idea con profesionales de la salud para encender el debate y llamar a la reflexión crítica, de modo tal que se pueda contribuir con el emprendimiento de diseños clínicos adecuados para validar los beneficios de utilizar altas dosis de vitamina D en beneficio de la salud pública y sobre todo en tiempos de esta emergencia por COVID-19. Abstract Although we lack enough evidence to justify supplementing with vitamin D in the prevention and treatment of COVID-19 infection, it is increasingly feasible that this hypothesis is valid. Two general underlying mechanisms should be considered. One would be the anti-infectious and immunomodulatory action that it exerts by improving intercellular barriers by stimulating innate immunity, as well as by modulating adaptive immunity. Also, vitamin D reduces the production of inflammatory cytokines, such as IL-2 and interferon-gamma (INFγ). More recently, multiple pleiotropic effects have been demonstrated on the actions of vitamin D at the anti-inflammatory and immunomodulatory level with positive results in studies with influenza, coronavirus, and other respiratory infections. An inverse relationship between serum vitamin D levels and the prevalence of the respiratory infectious disease has been described. Of interest, another mechanistic approach responds to considering the inhibition of the renin-angiotensin-aldosterone system (RAAS), which is exacerbated in COVID-19 infection because the virus binds to the enzyme ACE2, making more angiotensin II available to cause damage. Vitamin D inhibits mediators of RAAS -present in all cells of the body- and by inhibiting ACE activity and increasing ACE2, it lowers angiotensin II levels. We present studies with proposals for recommended doses of vitamin D, and although a single guideline is not specified, the possible benefits are promising. Finally, the purpose of this review is to share this idea with health professionals to ignite the debate and call for critical reflection, so that it can contribute to the undertaking of more and better clinical designs to validate the benefits of using high doses of vitamin D for the benefit of public health and especially in times of crisis for COVID-19.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1016/j.arteri.2020.05.003
bibo:pmid	32718670
has license	els-covid
sha1sum (hex)	7121dceecf9346e6f084559a033b73cc2aeb7b95
schema:url	https://doi.org/10.1016/j.arteri.2020.05.003
resource representing a document's title	El suplemento con altas dosis de vitamina D podría representar una alternativa promisoria para prevenir o tratar la infección por COVID-19
has PubMed Central identifier	PMC7256522
has PubMed identifier	32718670
schema:publication	Clin Investig Arterioscler
resource representing a document's body	covid:7121dceecf9346e6f084559a033b73cc2aeb7b95#body_text
is schema:about of	named entity 'alternativa' named entity 'el equipo' named entity 'esta' named entity 'TLR4' named entity 'como' named entity 'NF-κB' named entity 'IL-8' named entity 'ECA2' named entity 'mismo' named entity 'IL-10' named entity 'déficit' named entity 'la comunidad' named entity 'epidemia' named entity 'rotavirus' named entity 'tercio' named entity 'calcitriol' named entity 'Th1' named entity 'infiltrado' named entity 'IL-1β' named entity 'COVID-19' named entity 'HIV' named entity 'Llama' named entity 'IL-6' named entity 'esta' named entity 'COVID-19' named entity 'IL-2' named entity 'mismo' named entity 'Akt' named entity 'IL-10' named entity 'IL-4' named entity 'ECA2' named entity 'COVID-19' named entity 'COVID-19' named entity 'RANTES' named entity 'EPOC' named entity 'China' named entity 'NF-κB' named entity 'COVID-19' named entity 'mismo' named entity 'el espectro' named entity 'SARS-CoV-2' named entity 'la respuesta' named entity 'ECA2' named entity 'El efecto' named entity 'COVID-19' named entity 'hacer' named entity 'HIV' named entity 'COVID-19' named entity 'BRA' named entity 'EPOC' named entity 'Th2' named entity 'calcitriol' named entity 'CD80' named entity 'Ohio' named entity 'ECA2' named entity 'esta' named entity 'COVID-19' named entity 'apoptosis' named entity 'herpes virus' named entity 'el debate' named entity 'ECA2' named entity 'IL-6' named entity 'esta' named entity 'la liberación' named entity 'mismo' named entity 'alteran' named entity 'COVID-19' named entity 'puede ser' named entity 'BRA' named entity 'BRA' named entity 'TGF-β1' named entity 'Clinicaltrials.gov' named entity 'cascada' named entity 'BRA' named entity 'necrosis' named entity 'pre-eclampsia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software